Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2009 1
2012 3
2013 2
2014 4
2015 8
2016 5
2017 8
2018 11
2019 12
2020 15
2021 10
2022 14
2023 10
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: saadati m. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Gohring G, Behrens YL, Li Z, Dallmann LK, Klement P, Albert C, Wichmann M, Alwie Y, Benner A, Saadati M, Ganser A, Thol F, Heuser M. Shahswar R, et al. Among authors: saadati m. Haematologica. 2024 Jan 1;109(1):72-83. doi: 10.3324/haematol.2023.282912. Haematologica. 2024. PMID: 37470150 Free PMC article.
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, Döhner K, Döhner H. Jahn E, et al. Among authors: saadati m. Leukemia. 2023 Nov;37(11):2187-2196. doi: 10.1038/s41375-023-01999-6. Epub 2023 Aug 17. Leukemia. 2023. PMID: 37591941 Free PMC article.
Marginal variable screening for survival endpoints.
Edelmann D, Hummel M, Hielscher T, Saadati M, Benner A. Edelmann D, et al. Among authors: saadati m. Biom J. 2020 May;62(3):610-626. doi: 10.1002/bimj.201800269. Epub 2019 Aug 26. Biom J. 2020. PMID: 31448463 Review.
Nano and microparticle drug delivery systems for the treatment of Brucella infections.
Razei A, Javanbakht M, Hajizade A, Heiat M, Zhao S, Aghamollaei H, Saadati M, Khafaei M, Asadi M, Cegolon L, Keihan AH. Razei A, et al. Among authors: saadati m. Biomed Pharmacother. 2023 Dec 31;169:115875. doi: 10.1016/j.biopha.2023.115875. Epub 2023 Nov 16. Biomed Pharmacother. 2023. PMID: 37979375 Free article. Review.
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Döhner H, Döhner K. Jahn N, et al. Among authors: saadati m. Leukemia. 2022 Sep;36(9):2218-2227. doi: 10.1038/s41375-022-01650-w. Epub 2022 Aug 3. Leukemia. 2022. PMID: 35922444 Free PMC article. Clinical Trial.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: saadati m. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Appelbaum JS, et al. Among authors: saadati m. Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263433 No abstract available.
106 results